A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Legend Biotech Corporation LEGN

Promising (early) broader-coverage candidate · Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for on

On FrontierLab's discovery record since 2026-06-26 (8 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Promising (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-05), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)	56.4%
Gross margin	55%
Gross profits / assets	0.39
Rule of 40	44.5
Net margin	-11.9%
Cash runway (months)	57.2
PEG	—
Price / sales	3.1

Quality checklist

✓ Revenue growth — 56.4% (pass ≥ 20%)
✓ Capital efficiency
~ Gross margin — 55% (pass ≥ 60%)
✗ Gross-margin trend — -10.5 (pass ≥ 2)
✓ Share dilution — 0.5%

Fundamentals — snapshot as of 2026-08-05

Stage	Early
Share issuance (YoY)	0.5% · flat share count
Moat	—
TAM	—
P/E (trailing)	—
EPS (trailing)	$-1.37
Burn multiple	0.2
Gross-margin trend (pts)	-10.5
Cash / assets	0.52
Net debt / EBITDA	—
Statements as of	Q1 FY2026 · filed 2026-05-12

Momentum context — a snapshot from 2026-08-05, not current

Price at surface	$19.13 (as of 2026-08-05)
52-week range	$16.24 – $39.16
% off 52-wk high	-51.1%
RSI (14)	28
Relative volume	0.9×

Risk flags

Burning cash — operating margin is negative.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-08-05 (end-of-day). How grades are computed →